Abiopharma

Lillys Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive

Bristol Myers Squibb - BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Castle Biosciences - Expert Melanoma Panel Recommends CastleBiosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer

Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel